Context Therapeutics buys out future milestones and royalties for CT-202 from BioAtla for $6.5M total

Context Therapeutics Inc.

Paid $4.5M upfront and $2M due by Aug 1, 2026 to eliminate all future milestone/royalty obligations.
License becomes irrevocable, royalty-free, fully paid-up, and non-terminable.
BioAtla no longer entitled to future milestones or royalties for CT-202.
Phase 1 trial initiation for CT-202 expected in Q3 2026.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.99

Context Therapeutics Inc. amended First Amendment to License Agreement with BioAtla, Inc. valued at $4.5 million within five business days of the Amendment Date and an additional $2.0 million by Augus (effective 2026-05-14).

Action: amendment
Agreement: license
Counterparty: BioAtla, Inc.
Value: $4.5 million within five business days of the Amendment Date and an additional $2.0 million by Augus
Effective: 2026-05-14

Exact text from the filing

On May 14, 2026 (the “Amendment Date”), Context Therapeutics Inc. (the “Company”) entered into a First Amendment (the “Amendment”) to that certain License Agreement, dated September 23, 2024, by and between the Company and BioAtla, Inc. (“BioAtla”) (the “Original License Agreement”).

View on SEC.gov

Browse all material agreements →

Context Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001628280-26-035793

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.